Please sign in to follow a disease.
Pineoblastoma
MONDO:0016722Pineoblastoma is a rare, malignant type of supratentorial primitive neuroectodermal tumor (sPNET), found mainly in children (less than 10% of cases are reported in adults), and located in the pineal region of the brain but that can metastasize along the neuroaxis. As it is the most aggressive of the pineal parenchymal tumors, it is usually associated with a poor prognosis.
Also known as: PNET of pineal gland, PNET of the pineal gland, pineal PNET, pineal gland PNET, pineal gland primitive neuroectodermal neoplasm, pineal gland primitive neuroectodermal tumor, pineal gland primitive neuroectodermal tumour, pineal primitive neuroectodermal neoplasm
2850 clinical trials for this condition and its sub-types, 15 tagged with Pineoblastoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pineoblastoma
-
Adult pineoblastoma 0 trials
-
Nasal spray could deliver brain tumor treatment directly to Kids' tumors
Disease control Recruiting nowThis early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…
Phase 1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immune cells engineered to hunt brain tumors in kids
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack tumor cells, deliv…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immune cells engineered to fight brain cancer in kids
Disease control Recruiting nowThis early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …
Phase 1 • Sponsor: Robbie Majzner • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for toddlers with aggressive brain cancer: experimental spinal-fluid chemo
Disease control Recruiting nowThis early-phase study tests whether adding chemotherapy directly into the spinal fluid (intrathecal topotecan) followed by maintenance pills is feasible for children under 6 with high-risk embryonal brain tumors. About 15 children will receive this treatment after standard high-…
Early phase 1 • Sponsor: C17 Council • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Targeted radiation zaps childhood brain tumors in early trial
Disease control Recruiting nowThis phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Tailor-Made T-Cells take on childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough brain tumors: gene therapy meets immunotherapy and radiation
Disease control Recruiting nowThis early-phase trial is testing a combination of three treatments for children whose brain tumors have come back or not responded to standard care. The experimental drug SGT-53 delivers a normal TP53 gene to tumor cells, and is given alongside the immunotherapy Nivolumab and ra…
Early phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take aim at childhood brain cancers
Disease control Recruiting nowThis early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New study tracks memory loss in kids after brain radiation
Knowledge-focused Recruiting nowThis study looks at how radiation to the brain affects memory in children who had a brain tumor. Researchers will test memory and thinking skills in 130 children ages 4 to 12, starting 2 years after radiation and again 2 years later. The goal is to learn which parts of the brain …
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Global brain tumor registry aims to unlock secrets of rare childhood cancers
Knowledge-focused Recruiting nowThis international registry collects medical data and biological samples from children and adults with rare brain tumors like medulloblastoma and ependymoma. By gathering information from patients not in clinical trials, researchers hope to improve treatment recommendations and i…
Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC